Time filter

Source Type

Langford, United Kingdom

Bovens C.,University of Bristol | Tennant K.,Diagnostic Laboratories | Reeve J.,University of Bristol | Murphy K.F.,University of Bristol
Journal of Veterinary Internal Medicine | Year: 2014

Background: Measurement of basal serum or plasma cortisol concentration is used as a screening test for hypoadrenocorticism in dogs, but is not well characterized. Objectives: To evaluate the sensitivity and specificity of basal serum cortisol to detect hypoadrenocorticism in a population of dogs with a clinical suspicion of hypoadrenocorticism. Animals: Four hundred and fifty dogs with nonadrenal gland illness and 14 dogs with naturally occurring hypoadrenocorticism were included. Methods: Retrospective case-control study. The records of all dogs having had an ACTH stimulation test performed between January 2005 and September 2011 at the University of Bristol were reviewed. Dogs were included if the test was performed as a screening for hypoadrenocorticism. The sensitivity and specificity of basal serum cortisol concentration to detect dogs with hypoadrenocorticism were calculated using 2 cut-offs and compared to the gold standard ACTH stimulation test. Results: Using a cut-off of ≤2 μg/dL (≤55 nmol/L), the sensitivity and specificity of basal cortisol to detect hypoadrenocorticism were 100% and 63.3%, respectively, whereas for a cut-off of ≤1 μg/dL (≤28 nmol/L), the sensitivity and specificity were 85.7% and 91.8%, respectively. Conclusions and Clinical Importance: Measurement of basal serum cortisol is useful as a screening test for hypoadrenocorticism in dogs using a cut-off of ≤2 μg/dL (≤55 nmol/L), and the disease is unlikely with a basal serum cortisol >2 μg/dL (>55 nmol/L). A basal serum cortisol ≤2 μg/dL (≤55 nmol/L) cannot be used to diagnose hypoadrenocorticism, and an ACTH stimulation test should be performed in these cases. © 2014 by the American College of Veterinary Internal Medicine. Source

Al-Qudah K.M.,Jordan University of Science and Technology | Gharaibeh A.A.,Jordan University of Science and Technology | Al-Shyyab M.M.,Diagnostic Laboratories
Biological Trace Element Research | Year: 2010

The aim of this study was to determine the levels of trace minerals Zn, Cu, and Se, the effect of dermatophytosis on the level of thiobarbituric acid reactive substances (TBARS) as an indicator of lipid peroxidation, the status of enzymatic and nonenzymatic antioxidants, and the relationship between the mentioned trace minerals and antioxidant defense system in calves with dermatophytosis. A total of 21 Holstein calves with clinically established diagnosis of dermatophytosis and an equal number of healthy ones were included in this study. Results showed that 81% of mycotic isolates were Trichophyton verrucosum, while 19% were Trichophyton mentagrophytes. The level of Zn, Cu, Se, and glutathione (GSH) and the activity of the antioxidant enzymes, glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) were significantly (P∈≤∈0.05) lower. The plasma level of TBARS was significantly (P∈≤∈0.05) higher in dermatophytic calves compared to healthy controls. SOD activity was fairly correlated with serum Cu and positively correlated with serum Zn in healthy control (r∈=∈0.68, P∈≤∈0.05; r∈=∈0.58, P∈≤∈0.05) and in calves affected with dermatophytosis (r∈=∈0.73, P∈≤∈0.05; r∈=∈0.55, P∈≤∈0.05), respectively. GSH-Px activity was highly correlated with whole blood selenium (r∈=∈0.78, P∈≤∈0.05) in healthy control and dermatophytic subjects (r∈=∈0.76, P∈≤∈0.05). Our results demonstrated that in dermatophytosis, the alteration in the antioxidant enzyme activities might be secondary to changes in their cofactor concentrations. © 2009 Humana Press Inc. Source

Papaioannou A.,Education and Technological Institute of Larissa | Rigas G.,Education and Technological Institute of Larissa | Plageras P.,Education and Technological Institute of Larissa | Karikas G.A.,Technological Educational Institute of Athens | Karamanis G.,Diagnostic Laboratories
Journal of Clinical Laboratory Analysis | Year: 2013

Background: In recent years, the use of biochemical markers has received increasing attention for purposes of risk assessment and clinical management in renal failure patients. Chemometric methods are often used in medical studies and there are already indications for their specific role as a tool of the medical statistics. Methods: Three chemometric methods, discriminant analysis (DA), binary logistic regression analysis (BLRA), and cluster analysis (CA), were used for assessment and modeling of routinely used biochemical laboratory data of 18 parameters that were determined from 185 healthy individuals (HIs) and 173 end-stage renal failure (ESRF) patients. Results: The above-mentioned chemometric methods were performed using the data set of 14 parameters since the rest 4 parameters did not present significant difference between healthy and patients. DA created a model using only ALB (Albumin), K (Potassium), TG (Triglyceride), and ALP (Alkaline phosphatase); BLRA model also used the above four parameters; CA classified all the cases into two clusters using the same four parameters and one more parameter, AST (aspartate aminotransferase). Conclusions: This study provides models for assessment and modeling of routinely used biochemical laboratory data, finding groups of similarity among clinical tests usually determined on HIs and ESRF patients, contributing in data mining and reducing costs. © 2013 Wiley Periodicals, Inc. Source

News Article
Site: http://www.biosciencetechnology.com/rss-feeds/all/rss.xml/all

System allows pathology labs and others to match patients' test results to personalized cancer treatments, including clinical trials and experimental drugs, in real-time. MolecularMatch, a personalized cancer treatment company that works with labs, hospitals, genomic cores and physicians to connect cancer patients to treatment options, launched its MM LAB software today at The Molecular Medicine Tri-Conference. MM LAB, which is available through an online portal, allows pathology labs and others to match patients’ test results to personalized cancer treatments, including clinical trials and experimental drugs, in real-time. It is based on the already available, public-facing MolecularMatch cancer treatment search engine. “We’ve taken a time-consuming, manual task that usually happens after lab results are returned, and automated it with an intelligent, science-based, Google-like search,” said MolecularMatch CEO Kevin Coker. “With MM LAB, oncologists and patients get test results and easily understandable treatment options all at once, rather than having to wait even longer to find and begin a course of treatment.” After test results are matched to treatments in MM LAB, the options are curated by the client laboratory's staff and included in the reports sent back to physicians and patients. “MolecularMatch provides a powerful resource for molecular pathologists,” said Christopher Corless, MD, PhD., Chief Medical Officer of OHSU Knight Diagnostic Laboratories. “Identifying treatment options — particularly trials — is a time-consuming task. The MolecularMatch platform allows our team to efficiently match complex genomic test data to appropriate treatment options in much less time.”

Koukouvinos G.,Greek National Center For Scientific Research | Petrou P.,Greek National Center For Scientific Research | Misiakos K.,Greek National Center For Scientific Research | Drygiannakis D.,ThetaMetrisis S.A | And 8 more authors.
Biosensors and Bioelectronics | Year: 2015

A dual-analyte assay for the simultaneous determination of C-reactive protein (CRP) and D-dimer in human blood plasma based on a white light interference spectroscopy sensing platform is presented. Measurement is accomplished in real-time by scanning the sensing surface, on which distinct antibody areas have been created, with a reflection probe used both for illumination of the surface and collection of the reflected interference spectrum. The composition of the transducer, the sensing surface chemical activation and biofunctionalization procedures were optimized with respect to signal magnitude and repeatability. The assay format involved direct detection of CRP whereas for D-dimer a two-site immunoassay employing a biotinylated reporter antibody and reaction with streptavidin was selected. The assays were sensitive with detection limits of 25. ng/mL for both analytes, precise with intra- and inter-assay CV values ranging from 3.6% to 7.7%, and from 4.8% to 9.5%, respectively, for both assays, and accurate with recovery values ranging from 88.5% to 108% for both analytes. Moreover, the values determined for the two analytes in 35 human plasma samples were in excellent agreement with those received for the same samples by standard diagnostic laboratory instrumentation employing commercial kits. The excellent agreement of the results supported the validity of the proposed system for clinical application for the detection of multiple analytes since it was demonstrated that up to seven antibody areas can be created on the sensing surface and successfully interrogated with the developed optical set-up. © 2015. Source

Discover hidden collaborations